Looking for a discount stock with a good dividend yield? Then take a look at Stryker Corporation (NYSE:SYK).
With its cutting-edge technologies in robotics and minimally invasive surgery, Stryker Corporation is a leader in medical technology. With a strong presence in developed and emerging markets around the world, the company stands out for its innovation and commitment to improving medical care.
The company has demonstrated remarkable financial stability, reporting impressive results in the fourth quarter of 2024 with EPS of $4.01 and revenue of $6.4 billion, exceeding analysts' forecasts.
Consistent results are supported by a solid gross profit margin of 64 percent and return on invested capital of 13 percent, with an impressive 34-year history of dividend payments. Organic sales growth, at an annual rate of 10.2 percent, is a sign of the company's strong market presence and operational efficiency.
Stryker recently acquired Inari Medica for $4.9 billion, marking its entry into the mechanical thrombectomy market. This strategic move demonstrates the company's commitment to optimize its portfolio and grow into new high-potential markets. At the same time, Stryker divested its spinal implant business as part of its repositioning strategy.
In the long term, the management team expects organic sales growth of 9.75-10 percent by 2025. This growth will be supported by expansion initiatives in Europe, emerging markets, and the Asia-Pacific regions.
I am confident in the potential of this stock and have decided to add it to my portfolio. By expanding into high-growth markets, such as mechanical thrombectomy through the acquisition of Inari Medical (NASDAQ:NARI), Stryker should achieve significant revenue growth and exceed annual market growth rates of 20 percent.
Focusing on international expansion, especially in emerging markets, could open up new revenue opportunities due to increased demand for advanced medical technologies and expanding healthcare infrastructure.
Stryker's dedication to innovation, whether through internal development or strategic acquisitions, will likely be an important factor in maintaining its leading position in various segments of medical technology. This ongoing commitment to innovation will also strengthen its competitive position in the market.
Through constant investment in research and development, the company is committed to integrating cutting-edge technologies to create innovative products. These products not only address unmet medical needs, but are also available at a price that is affordable to all.
There are certain characteristics that define successful companies. For example, a steady increase in dividends for 15 consecutive years and a leading position in their industry. Here is a clear example of this concept.
From a technical point of view, the trend is clearly defined and my target for this stock is $465.
There is also good news on seasonality: last March the stock was up 20 percent.
In summary, Stryker is an exceptional company with a long history of innovation in medical devices. Its diversified business has led to steady growth in revenues and profits for many decades.
This has been made possible through significant investment in research and development as well as its acquisition strategy. The company still has many opportunities for growth, both in the United States, where healthcare spending is increasing due to an aging population, and internationally, where there is still a large untapped market.